This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Superoxide Dismutase (SOD) as Antioxidant Treatment OF Age Related Macular Degeneration (ARMD)

This study has been completed.
Information provided by:
Centre de Recherche en Nutrition Humaine Rhone-Alpe Identifier:
First received: December 2, 2008
Last updated: NA
Last verified: December 2008
History: No changes posted


Acting directly on the anti-radical enzyme chain, the superoxide dismutase (SOD), a major enzyme of the anti-oxidant system, provides an alternative of the antioxidants treatment in ARMD. Its synthesis depends on the cellular oxygenated reactive species, and leads to the conversion of the superoxide ion (O2-) into hydrogen peroxide (H2O2). This compound is the cell watch guard continuously regulating a free radicals' detoxifying chain. Subsequently, by increasing the production of H2O2, the administration of SOD can trigger endogenous/internal antioxidant mechanisms.

Oral administration of SOD is possible in its galenic form, Glisodine. The purpose of this study was to evaluate the protective effect of SOD on the bilateralization of the disease.

Condition Intervention Phase
Age Related Macular Degeneration Dietary Supplement: SOD Dietary Supplement: Sham Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: SOD as Antioxidant Treatment OF ARMD

Resource links provided by NLM:

Further study details as provided by Centre de Recherche en Nutrition Humaine Rhone-Alpe:

Primary Outcome Measures:
  • difference on AREDS score, Month 24 - Month 0 [ Time Frame: 24 months ]

Enrollment: 46
Study Start Date: September 2005
Study Completion Date: June 2008
Primary Completion Date: April 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Sham Comparator: Control Dietary Supplement: Sham
Experimental: SOD Dietary Supplement: SOD


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • unilateral neo-vascular ARMD

Exclusion Criteria:

  • other pathology
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00800995

Centre Hospitalier Universitaire de Grenoble
Grenoble, France, 38043
Sponsors and Collaborators
Centre de Recherche en Nutrition Humaine Rhone-Alpe
  More Information

Responsible Party: Pr Romanet, CHU Grenoble Identifier: NCT00800995     History of Changes
Other Study ID Numbers: CHUG-0501
Study First Received: December 2, 2008
Last Updated: December 2, 2008

Keywords provided by Centre de Recherche en Nutrition Humaine Rhone-Alpe:

Additional relevant MeSH terms:
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Superoxide Dismutase
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs
Free Radical Scavengers processed this record on August 23, 2017